<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961167</url>
  </required_header>
  <id_info>
    <org_study_id>VBX 13-05</org_study_id>
    <nct_id>NCT01961167</nct_id>
  </id_info>
  <brief_title>Evaluation of the GORE速 VIABAHN速 BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX)</brief_title>
  <official_title>Evaluation of the GORE速 VIABAHN速 BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX) for the Treatment of Occlusive Disease in the Common and External Iliac Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the VBX13-05 clinical study is to evaluate the safety and efficacy
      of VIABAHN BX for the treatment of arterial occlusive disease in patients with de novo or
      restenotic lesions in the common and/or external iliac arteries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 14, 2017</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Major Adverse Events (MAEs)</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of study subjects experiencing a major adverse event (MAE) defined as:
Device- or procedure-related death within 30 days of the index procedure; and
Myocardial Infarction (MI) occurring within 30 days of the index procedure; and
Amputation above the metatarsals in the treated leg, resulting from a vascular event, occurring within 30 days of the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Success</measure>
    <time_frame>Discharge</time_frame>
    <description>Number of subjects who experience acute procedural success defined as less than or equal to 30% residual stenosis prior to procedure completion and no device- or procedure-related SAEs before discharge at day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirty-day Clinical Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of subjects who experienced 30-day clinical success defined as an improvement of at least one Rutherford Category at the 30-day visit as compared to pre-procedure and no device- or procedure-related serious adverse events (SAEs) within 30 days of the index procedure.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of primary patency at 30 days. Primary patency is defined as blood flow in the treated segment(s), without reintervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>6 Months</time_frame>
    <description>Kaplan-Meier estimate of primary patency at 6 months. Primary patency is defined as blood flow in the treated segment(s), without reintervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of primary assisted patency at 30 days. Primary assisted patency is defined as blood flow maintained with or without reintervention in the originally treated segment(s), including the proximal and distal margins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>6 Months</time_frame>
    <description>Kaplan-Meier estimate of primary assisted patency at 6 Months. Primary assisted patency is defined as blood flow maintained with or without reintervention in the originally treated segment(s), including the proximal and distal margins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of secondary patency at 30 days. Secondary patency is defined as presence of blood flow, with or without reintervention, in the originally treated segment(s), including the proximal and distal margins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>6 Months</time_frame>
    <description>Kaplan-Meier estimate of secondary patency at 6 months. Secondary patency is defined as presence of blood flow, with or without reintervention, in the originally treated segment(s), including the proximal and distal margins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Lesion(s) Revascularization (TLR)</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 30 days. TLR is defined as revascularization occurring within the treated segment(s) by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Lesion(s) Revascularization (TLR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 6 months. TLR is defined as revascularization occurring within the treated segment(s) by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 30 days. TVR is defined as revascularization of the vessel treated at the time of the index procedure by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 6 months. TVR is defined as revascularization of the vessel treated at the time of the index procedure by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Change in Rutherford Category</measure>
    <time_frame>30 Days</time_frame>
    <description>Change in Rutherford Category from pre-procedure at 30 days.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Rutherford Category</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in Rutherford Category from pre-procedure at 6 months.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>30 Days</time_frame>
    <description>Change in Ankle Brachial Index (ABI) from pre-procedure at 30 days. Larger values indicate a better outcome. The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in Ankle Brachial Index(ABI) from pre-procedure at 6 months. Larger values indicate a better outcome.The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Major Adverse Events (MAEs)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of subjects experiencing freedom from procedure- or device-related events causing death, occurring within 30 days of the index procedure; and myocardial infarction (MI) occurring within 30 days of the index procedure; and target lesion revascularization (TLR) occurring within 6 months of the index procedure; and major amputation of the treated leg(s), resulting from a vascular event, occurring within 6 months of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D- Mobility</measure>
    <time_frame>30 days</time_frame>
    <description>Change in functional status (EQ5D - Mobility) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D- Mobility</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in functional status (EQ5D - Mobility) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>30 days</time_frame>
    <description>Change in functional status (EQ5D - Self Care) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in functional status (EQ5D - Self Care) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>30 days</time_frame>
    <description>Change in functional status (EQ5D - Usual Activities) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in functional status (EQ5D - Usual Activities) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>30 Days</time_frame>
    <description>Change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>30 Days</time_frame>
    <description>Change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D- Own Health State</measure>
    <time_frame>30 Days</time_frame>
    <description>Change in functional status (EQ5D - Own Health State) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status - EQ5D- Own Health State</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in functional status (EQ5D - Own Health State) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Differential Diagnoses at 30 Days - Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>30 day</time_frame>
    <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Differential Diagnoses at 180 Days - Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>6 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 180 days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device or Procedure-related Death</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of subjects experiencing a device or procedure-related death within 30 days - component of primary outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom From Myocardial Infarction (MI)</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of subjects experiencing a myocardial infarction (MI) within 30 days - component of primary outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom From Major Amputation of the Treated Leg(s)</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of subjects experiencing a major amputation of the treated leg(s), resulting from a vascular event within 6 months - component</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Common Iliac Artery Occlusive Disease</condition>
  <condition>External Iliac Artery Occlusive Disease</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Gore VIABAHN BX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon expandable stenting of iliac occlusive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stenting of common and/or external iliacs</intervention_name>
    <description>Balloon expandable stenting of iliac occlusive disease</description>
    <arm_group_label>Gore VIABAHN BX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is at least 18 years old;

          -  Patient is male, infertile female, or female of childbearing potential practicing an
             acceptable method of preventing pregnancy;

          -  Patient or legal representative is willing to give written informed consent;

          -  Patient is capable of complying with protocol requirements, including all follow-up
             visits;

          -  Patient has symptomatic claudication or rest pain without tissue loss (Rutherford
             Categories 2-4).

          -  Patient has de novo or restenotic target lesion(s) in the common and/or external iliac
             artery

        Exclusion Criteria:

          -  Patient has a life expectancy of less than 1 year;

          -  Patient has a known allergy to stent graft components, including stainless steel or
             heparin;

          -  Patient has a known intolerance to antiplatelet, anticoagulant, or thrombolytic
             medications that would prevent compliance with the protocol;

          -  Patient has a condition (unrelated to the study) that is expected to require
             indefinite, or lifelong, anticoagulation

          -  Patient has had vascular access / catheterization in the lower extremity within 30
             days of study enrollment;

          -  Patient has had a previous or planned coronary intervention within 30 days prior to
             enrollment in this study or required at time of study procedure; Patient has had a
             previous or planned bypass surgery in the target leg, or a bypass that occurs at the
             time of the study procedure;

          -  Patient is currently participating in this or another investigative clinical study.

          -  Patient has evidence of angiographically visible thrombus within or adjacent to the
             target lesion(s);

          -  Patient has aneurysmal dilation proximal or distal to the target lesion(s) that would
             interfere with the placement of the device;

          -  Patient has a target lesion requiring atherectomy or any ablative device to facilitate
             stent delivery;

          -  Patient has a target lesion situated in such a way that an implanted device will
             prevent blood flow or perfusion to the internal iliac artery if patent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Holden, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>June 29, 2017</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2019</results_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>Stent</keyword>
  <keyword>Claudication</keyword>
  <keyword>VIABAHN</keyword>
  <keyword>Gore</keyword>
  <keyword>Endoprosthesis</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Iliac Occlusive Disease</keyword>
  <keyword>Balloon Expandable</keyword>
  <keyword>Stent Graft</keyword>
  <keyword>VBX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gore VIABAHN BX</title>
          <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects meeting all eligibility criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Iliac Stenting</title>
          <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Major Adverse Events (MAEs)</title>
        <description>Percentage of study subjects experiencing a major adverse event (MAE) defined as:
Device- or procedure-related death within 30 days of the index procedure; and
Myocardial Infarction (MI) occurring within 30 days of the index procedure; and
Amputation above the metatarsals in the treated leg, resulting from a vascular event, occurring within 30 days of the index procedure.</description>
        <time_frame>30 days</time_frame>
        <population>Population includes enrolled subjects who either experienced the defined event or were followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Major Adverse Events (MAEs)</title>
          <description>Percentage of study subjects experiencing a major adverse event (MAE) defined as:
Device- or procedure-related death within 30 days of the index procedure; and
Myocardial Infarction (MI) occurring within 30 days of the index procedure; and
Amputation above the metatarsals in the treated leg, resulting from a vascular event, occurring within 30 days of the index procedure.</description>
          <population>Population includes enrolled subjects who either experienced the defined event or were followed for at least 30 days.</population>
          <units>percentage of subjects experiencing MAE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Procedural Success</title>
        <description>Number of subjects who experience acute procedural success defined as less than or equal to 30% residual stenosis prior to procedure completion and no device- or procedure-related SAEs before discharge at day 1.</description>
        <time_frame>Discharge</time_frame>
        <population>Population includes subjects followed through discharge at day 1 and had relevant procedural data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedural Success</title>
          <description>Number of subjects who experience acute procedural success defined as less than or equal to 30% residual stenosis prior to procedure completion and no device- or procedure-related SAEs before discharge at day 1.</description>
          <population>Population includes subjects followed through discharge at day 1 and had relevant procedural data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thirty-day Clinical Success</title>
        <description>Number of subjects who experienced 30-day clinical success defined as an improvement of at least one Rutherford Category at the 30-day visit as compared to pre-procedure and no device- or procedure-related serious adverse events (SAEs) within 30 days of the index procedure.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Thirty-day Clinical Success</title>
          <description>Number of subjects who experienced 30-day clinical success defined as an improvement of at least one Rutherford Category at the 30-day visit as compared to pre-procedure and no device- or procedure-related serious adverse events (SAEs) within 30 days of the index procedure.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Kaplan-Meier estimate of primary patency at 30 days. Primary patency is defined as blood flow in the treated segment(s), without reintervention.</description>
        <time_frame>30 Days</time_frame>
        <population>Analysis includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Kaplan-Meier estimate of primary patency at 30 days. Primary patency is defined as blood flow in the treated segment(s), without reintervention.</description>
          <population>Analysis includes subjects followed for at least 30 days and had relevant data.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Kaplan-Meier estimate of primary patency at 6 months. Primary patency is defined as blood flow in the treated segment(s), without reintervention.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 180 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Kaplan-Meier estimate of primary patency at 6 months. Primary patency is defined as blood flow in the treated segment(s), without reintervention.</description>
          <population>Population includes subjects followed for at least 180 days and had relevant data.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Assisted Patency</title>
        <description>Kaplan-Meier estimate of primary assisted patency at 30 days. Primary assisted patency is defined as blood flow maintained with or without reintervention in the originally treated segment(s), including the proximal and distal margins.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Assisted Patency</title>
          <description>Kaplan-Meier estimate of primary assisted patency at 30 days. Primary assisted patency is defined as blood flow maintained with or without reintervention in the originally treated segment(s), including the proximal and distal margins.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Assisted Patency</title>
        <description>Kaplan-Meier estimate of primary assisted patency at 6 Months. Primary assisted patency is defined as blood flow maintained with or without reintervention in the originally treated segment(s), including the proximal and distal margins.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 180 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Assisted Patency</title>
          <description>Kaplan-Meier estimate of primary assisted patency at 6 Months. Primary assisted patency is defined as blood flow maintained with or without reintervention in the originally treated segment(s), including the proximal and distal margins.</description>
          <population>Population includes subjects followed for at least 180 days and had relevant data.</population>
          <units>Lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>Kaplan-Meier estimate of secondary patency at 30 days. Secondary patency is defined as presence of blood flow, with or without reintervention, in the originally treated segment(s), including the proximal and distal margins.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>Kaplan-Meier estimate of secondary patency at 30 days. Secondary patency is defined as presence of blood flow, with or without reintervention, in the originally treated segment(s), including the proximal and distal margins.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>Kaplan-Meier estimate of secondary patency at 6 months. Secondary patency is defined as presence of blood flow, with or without reintervention, in the originally treated segment(s), including the proximal and distal margins.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 180 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>Kaplan-Meier estimate of secondary patency at 6 months. Secondary patency is defined as presence of blood flow, with or without reintervention, in the originally treated segment(s), including the proximal and distal margins.</description>
          <population>Population includes subjects followed for at least 180 days and had relevant data.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Lesion(s) Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 30 days. TLR is defined as revascularization occurring within the treated segment(s) by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Lesion(s) Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 30 days. TLR is defined as revascularization occurring within the treated segment(s) by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
          <population>Population includes subjects followed for at least 30 days.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Lesion(s) Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 6 months. TLR is defined as revascularization occurring within the treated segment(s) by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 180 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Lesion(s) Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 6 months. TLR is defined as revascularization occurring within the treated segment(s) by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
          <population>Population includes subjects followed for at least 180 days.</population>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 30 days. TVR is defined as revascularization of the vessel treated at the time of the index procedure by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 30 days. TVR is defined as revascularization of the vessel treated at the time of the index procedure by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
          <population>Population includes subjects followed for at least 30 days.</population>
          <units>Vessel</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 6 months. TVR is defined as revascularization of the vessel treated at the time of the index procedure by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 180 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 6 months. TVR is defined as revascularization of the vessel treated at the time of the index procedure by means of a percutaneous vascular intervention, surgical bypass, thrombolysis, or other invasive means.</description>
          <population>Population includes subjects followed for at least 180 days.</population>
          <units>percentage of vessel</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Change in Rutherford Category</title>
        <description>Change in Rutherford Category from pre-procedure at 30 days.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change in Rutherford Category</title>
          <description>Change in Rutherford Category from pre-procedure at 30 days.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Rutherford Category</title>
        <description>Change in Rutherford Category from pre-procedure at 6 months.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Rutherford Category</title>
          <description>Change in Rutherford Category from pre-procedure at 6 months.
Rutherford categories include:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsended</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Change in Ankle Brachial Index (ABI) from pre-procedure at 30 days. Larger values indicate a better outcome. The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Change in Ankle Brachial Index (ABI) from pre-procedure at 30 days. Larger values indicate a better outcome. The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".15" lower_limit="-0.16" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Change in Ankle Brachial Index(ABI) from pre-procedure at 6 months. Larger values indicate a better outcome.The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Change in Ankle Brachial Index(ABI) from pre-procedure at 6 months. Larger values indicate a better outcome.The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".15" lower_limit="-0.17" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Major Adverse Events (MAEs)</title>
        <description>Number of subjects experiencing freedom from procedure- or device-related events causing death, occurring within 30 days of the index procedure; and myocardial infarction (MI) occurring within 30 days of the index procedure; and target lesion revascularization (TLR) occurring within 6 months of the index procedure; and major amputation of the treated leg(s), resulting from a vascular event, occurring within 6 months of the index procedure.</description>
        <time_frame>6 months</time_frame>
        <population>Population includes number of subjects enrolled into the study who either had defined event or were followed for at least 150 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Major Adverse Events (MAEs)</title>
          <description>Number of subjects experiencing freedom from procedure- or device-related events causing death, occurring within 30 days of the index procedure; and myocardial infarction (MI) occurring within 30 days of the index procedure; and target lesion revascularization (TLR) occurring within 6 months of the index procedure; and major amputation of the treated leg(s), resulting from a vascular event, occurring within 6 months of the index procedure.</description>
          <population>Population includes number of subjects enrolled into the study who either had defined event or were followed for at least 150 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D- Mobility</title>
        <description>Change in functional status (EQ5D - Mobility) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>30 days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D- Mobility</title>
          <description>Change in functional status (EQ5D - Mobility) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D- Mobility</title>
        <description>Change in functional status (EQ5D - Mobility) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>6 Months</time_frame>
        <population>Patient population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D- Mobility</title>
          <description>Change in functional status (EQ5D - Mobility) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Patient population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Self Care</title>
        <description>Change in functional status (EQ5D - Self Care) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>30 days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Self Care</title>
          <description>Change in functional status (EQ5D - Self Care) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Self Care</title>
        <description>Change in functional status (EQ5D - Self Care) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Self Care</title>
          <description>Change in functional status (EQ5D - Self Care) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Change in functional status (EQ5D - Usual Activities) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>30 days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Change in functional status (EQ5D - Usual Activities) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Change in functional status (EQ5D - Usual Activities) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Change in functional status (EQ5D - Usual Activities) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D- Own Health State</title>
        <description>Change in functional status (EQ5D - Own Health State) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D- Own Health State</title>
          <description>Change in functional status (EQ5D - Own Health State) from pre-procedure at 30 days. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status - EQ5D- Own Health State</title>
        <description>Change in functional status (EQ5D - Own Health State) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status - EQ5D- Own Health State</title>
          <description>Change in functional status (EQ5D - Own Health State) from pre-procedure at 6 months. EQ5D is a standard instrument for use as a measure of health outcome.</description>
          <population>Population includes subjects followed for at least 150 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Differential Diagnoses at 30 Days - Walking Impairment Questionnaire (WIQ)</title>
        <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 30 days.</description>
        <time_frame>30 day</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Differential Diagnoses at 30 Days - Walking Impairment Questionnaire (WIQ)</title>
          <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Differential Diagnoses at 180 Days - Walking Impairment Questionnaire (WIQ)</title>
        <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 180 days.</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 6 Months and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Differential Diagnoses at 180 Days - Walking Impairment Questionnaire (WIQ)</title>
          <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 180 days.</description>
          <population>Population includes subjects followed for at least 6 Months and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device or Procedure-related Death</title>
        <description>Number of subjects experiencing a device or procedure-related death within 30 days - component of primary outcome.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Device or Procedure-related Death</title>
          <description>Number of subjects experiencing a device or procedure-related death within 30 days - component of primary outcome.</description>
          <population>Population includes subjects followed for at least 30 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Freedom From Myocardial Infarction (MI)</title>
        <description>Number of subjects experiencing a myocardial infarction (MI) within 30 days - component of primary outcome.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Myocardial Infarction (MI)</title>
          <description>Number of subjects experiencing a myocardial infarction (MI) within 30 days - component of primary outcome.</description>
          <population>Population includes subjects followed for at least 30 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Freedom From Major Amputation of the Treated Leg(s)</title>
        <description>Number of subjects experiencing a major amputation of the treated leg(s), resulting from a vascular event within 6 months - component</description>
        <time_frame>6 Months</time_frame>
        <population>Population includes subjects followed for at least 150 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Major Amputation of the Treated Leg(s)</title>
          <description>Number of subjects experiencing a major amputation of the treated leg(s), resulting from a vascular event within 6 months - component</description>
          <population>Population includes subjects followed for at least 150 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Iliac Stenting</title>
          <description>Balloon expandable stenting of iliac occlusive disease
Stenting of common and/or external iliacs: Balloon expandable stenting of iliac occlusive disease</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Leg ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Zambeck</name_or_title>
      <organization>W. L. Gore &amp; Associates</organization>
      <phone>928-856-4900</phone>
      <email>mzambeck@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

